If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
143
results.
Updated on
19/07/2025 [07:15:00]
Results 75 to 100 of 143
Absstract of: US2025186374A1
SARS-CoV-2 has raised the alarm to search for effective therapy for this virus. To date several vaccines have been approved, but few available drugs reported recently still need approval from FDA. Antiviral compositions having niclosamide derivatives were prepared for treating COVID-19. Using a FRET-based enzymatic assay, three niclosamide derivatives, JMX0286, JMX0301, and JMX0941, were identified as potent allosteric inhibitors against SARS-CoV-2 3CLpro, with IC50 values similar to that of known covalent inhibitor boceprevir. In a cell-based antiviral assay, these inhibitors can inhibit the virus growth with EC50 in the range of 2-3 μM. The mechanism of action of JMX0286, JMX0301, and JMX0941 were characterized by enzyme kinetics, affinity binding and protein-based substrate digestion. Molecular docking suggested that JMX0286, JMX0301, and JMX0941 bind specifically to an allosteric pocket of the SARS-CoV-2 3CL protease.
Absstract of: US2025188542A1
The present disclosure encompasses systems, methods, and compositions for enriching a population of rare circulating cells, including progenitor cells, from peripheral blood. Specific embodiments encompass methods of analyzing rare circulating cell transcriptomic, genetic, protein expression, metabolic, epigenomic, and/or other functional assay data to identify differential gene or protein expression and/or chromatin accessibility, and/or functional characteristics. Particular methods relate to enriching and analyzing rare circulating cells in patients following COVID-19 infection, and treating the patient based on the analysis. Embodiments also relate to an enriched population of rare circulating cells from peripheral blood and uses thereof.
Absstract of: AU2023400919A1
The present invention relates generally to a method of formulation of cannabidiol (CBD) a potential anti-inflammatory drug derived from lemon peel (d-limonene). More, particularly, the present invention relates to the enhancement of lipid soluble CBD into water soluble form in order to improve the formulation of the active component while apply in human for medication. The present invention further provides the therapeutic application of the new formulation which either neutralize and/or decreases the capability of the production of cytokines by activated immune cells during inflammatory process and hence alleviate the sufferings of illness like COVID-19 caused by SARSCoV2.
Absstract of: WO2025121804A1
Disclosed are a peptide, an antibody or an antigen-binding fragment thereof, a nucleic acid, a recombinant expression vector, a cell, a substance for detecting porcine epidemic diarrhea virus, a one-step diagnostic kit for porcine epidemic diarrhea, and a one-step diagnostic method for porcine epidemic diarrhea. Disclosed are a peptide, an antibody or an antigen-binding fragment thereof, a nucleic acid, a recombinant expression vector, a cell, a substance for detecting SARS-CoV-2 nucleoprotein, a one-step SARS-CoV-2 diagnostic kit, and a one-step SARS-CoV-2 diagnostic method.
Absstract of: US2025188102A1
A triazine compound, an intermediate thereof, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a triazine derivative as represented by formula (I′) or a pharmaceutically acceptable salt thereof. On the basis of retaining the effectiveness against SARS-CoV-2, the compound significantly prolongs the half-life period, reduces the dosage requirement, reduces side effects, expands the range of therapeutic window, and has very good prospects when used for manufacturing a drug for treating diseases related to coronavirus infections.
Absstract of: KR20250085005A
펩타이드, 항체 또는 이의 항원 결합 단편, 핵산, 재조합 발현 벡터, 세포, SARS-CoV-2 핵단백질 검출용 물질, 원스텝 SARS-CoV-2 진단 키트 및 원스텝 SARS-CoV-2 진단 방법이 개시된다.
Absstract of: US2025186443A1
The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.
Absstract of: US2025188155A1
Disclosed are a preparation method and application of a single-chain antibody fragment targeting SARS-COV-2 nucleocapsid protein, aiming to provide a single-chain antibody fragment with high affinity and strong specificity. The present disclosure obtains three single-chain antibody fragments targeting SARS-COV-2 nucleocapsid protein through construction of a nanobody phage library and phage screening technology. The single-chain antibody fragment consists of a heavy chain variable region, a 15aa connecting peptide, and a light chain variable region connected in sequence, and has an amino acid sequence shown in SEQ ID NO: 1-SEQ ID NO: 3. The single-chain antibody fragment in the present disclosure has excellent binding performance and specificity with the SARS-COV-2 nucleocapsid protein, can be applied to a variety of immunoassay platforms of the SARS-COV-2, and has broad application prospects in the field of SARS-COV-2 detection.
Absstract of: US2024166587A1
The invention discloses a compound with the general formula (I) wherein R1 to R6 are identical or not and are H, OH—, or OR7, wherein R7 is a C1 to C3 alkyl group or a C1 to C4 acyl group, with the proviso that at least four of R1 to R6 are different than H, for use in the treatment and prevention of COVID-19 in a human subject, especially for inhibiting SARS-CoV-2.
Absstract of: EP4566625A1
The present invention relates to a production method of an inactivated SARS-CoV-2 vaccine, the method including: a step of bringing a SARS-CoV-2 containing solution or an inactivated SARS-CoV-2 containing solution into contact with a cellulose sulfate ester gel at a pH of 8 or more and 10 or less to adsorb the SARS-CoV-2 or the inactivated SARS-CoV-2 to the gel; then removing impurities; and then eluting and recovering the SARS-CoV-2 or the inactivated SARS-CoV-2.
Absstract of: CN119731159A
The present disclosure relates to compounds of formula (I): # imgabs0 # and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of viral infections, such as coronavirus infections.
Absstract of: US12324835B1
An mRNA molecule is disclosed. The mRNA molecule contains a polynucleotide encoding an M1R antigen of Mpox and a polynucleotide encoding an RBD antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and further contains a polynucleotide encoding an A35R antigen of Mpox. An application of the mRNA molecule in the preparation of an mRNA vaccine against Mpox or SARS-CoV-2 is further disclosed. Compared to an mRNA vaccine encoding separately corresponding antigens, the provided mRNA vaccine encoding a fusion antigen can induce considerable or even higher-level neutralizing antibody responses against Mpox and SARS-CoV-2, and provides 100% immune protection against the lethal challenge of ectromelia virus. The vaccine is obtained by synthesizing a single mRNA molecule and encapsulating the single mRNA within lipid nanoparticles. Therefore, the single-component fusion mRNA vaccine has a wider application prospect than multivalent mRNA vaccine compositions.
Absstract of: KR20250083067A
본 발명은 계통수 분석 기반 교차 면역원성을 갖는 SARS-CoV-2 스파이크 모자이크 항원 및 이를 포함하는 백신에 관한 것으로서, 본 발명의 SARS-CoV-2 바이러스 모자이크 항원은 SARS-CoV-2 바이러스 변이주의 스파이크 단백질 서열을 모자이크 기법을 통해 조합하고 추가적인 아미노산 잔기를 치환하여, 초기 prototype, 알파 변이주, 베타 변이주, 감마 변이주, 델타 변이주 및 오미크론 변이주 등과 같은 다양한 SARS-CoV-2 변이주에 대한 범용성을 가지는 백신의 용도로서 유용하게 사용될 수 있다.
Absstract of: US2025180560A1
Provided herein are, in various embodiments, methods and kits for assaying one or more virions. In certain embodiments, the methods and kits of the disclosure provide for the calculation of virion titer and/or virion infectivity. In still further embodiments, the disclosure provides for methods and kits for enhancing assaying of viruses such as SARS-CoV-2.
Absstract of: US2025177428A1
Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.
Absstract of: US2025177434A1
An antiviral agent is provided, having a phosphorodiamidate morpholino oligomer with an antisense sequence to a portion of a genome of a strain of a coronavirus. The coronavirus may be SARS-CoV-2 or another βCoV. The antiviral agent finds many uses, such as in a pharmaceutical composition, a method of treating coronavirus-mediated disease, a method of preventing coronavirus-mediated disease, a method of reducing or preventing the replication of coronavirus in a host cell, a method of controlling the spread of coronavirus in donated tissue, a treated tissue sample, and in the manufacture of a medicament for the treatment or prevention or coronavirus-mediated disease.
Absstract of: US2025177481A1
The invention relates to polypeptides derived from SCO-spondin for increasing or enhancing the basal excitatory synaptic transmission, notably glutamatergic neurotransmission. More particularly the invention relates to said polypeptides for increasing or enhancing glutamatergic neurotransmission in diseases or conditions comprising psychiatric disorders; drug addiction; viral infection (such as coronaviruses, e.g. SARS CoV2) related neurological symptoms; NMDA receptor (NMDAr) and/or AMPA receptor (AMPAr) deficiency related disease, notably anti-NMDAr encephalitis; vegetative state, and hypoxic brain injury. The present invention also relates to methods of treatment.
Absstract of: US2025180506A1
This present invention provides a system, method, and device for rapidly screening individuals at a high rate of speed. The invention features a method, system and device that analyzes an individual's body odors to determine the presence or absence of a disease such as COVID-19 and/or its variants. The invention allows for real-time testing for a pathogen, a disease, or other condition of interest that is especially useful when testing every individual entering or exiting a venue or transitioning through any controlled entry or exit zone demarcated by a portal, passage, security zone, or gate, etc. This testing requires no invasive sampling—or even touch contact—between the device or device operator and the person being tested. The device features a sensing surface whose electronic activity is a function volatile organic compounds (body odor) in the immediate vicinity of its surface.
Absstract of: AU2025203389A1
Abstract A vaccine composition comprising a lyophilized, adenovirus-based expression vector encoding a disease antigen, and a stabilizing compound, such as aragonite. The disease antigen may comprise a viral protein or fragment thereof, such as a SARS-CoV2 virus protein. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.
Absstract of: US2025179151A1
Provided are methods for treating viral infections in subject in need thereof. In some embodiments, the method include administering to the subject a composition that has an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike. Also provided are compositions that include an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike, which compositions can optionally be employed in the disclosed methods.
Absstract of: US2025177541A1
Disclosed herein are methods of treating a lung disorder. In some embodiments, the lung disorder includes an acute respiratory syndrome. In some embodiments, the treatment includes administering to a subject in need thereof, a modified Serp-1 protein. The modified Serp-1 protein may include a therapeutic enhancing moiety. In some embodiments, the therapeutic enhancing moiety is a water soluble polymer such as polyethylene glycol.
Absstract of: US2025179581A1
Methods and devices for utilizing reverse transcription loop-mediated isothermal amplification (RT-LAMP) to detect target DNA and RNA sequences for diagnostic and experimental assays, such as those for diagnosing and quantifying diseases, such as colorectal cancer and gastrointestinal disease, or pathogens, such as SARS-COV-2.
Absstract of: US2025177469A1
The present invention relates to a use of a novel Sanguisorba officinalis Linne extract to inhibit SARS-CoV-2 virus 3CL protease and RdRp activity. The composition including the Sanguisorba officinalis Linne extract of the present invention as an active ingredient inhibits 3CL protease and RdRp activity and thus is effective in preventing or treating infection by SARS-CoV-2 and a variant virus thereof.
Absstract of: US2025179152A1
The present disclosure relates to compositions and methods for the treatment and/or prevention of SARS-COV-2 infections. In one embodiment the method comprises the delivery of a pharmaceutical composition comprising a SARS-COV-2 neutralizing synthetic protein, optionally wherein the protein is a trimeric protein composed of designed ankyrin repeat protein (DARPin) fused with a T4 foldon peptide that is administered non-invasively such as by nasal inhalation.
Nº publicación: KR20250077973A 02/06/2025
Applicant:
한국기초과학지원연구원대한민국질병관리청국립보건연구원장
Absstract of: KR20250077973A
본 발명은 개체의 아르기닌(Arginine) 대사경로 활성화를 확인하는 단계;를 포함하는, COVID-19 코로나바이러스 변이주 감염의 모니터링 방법에 관한 것으로, 본 발명의 모니터링 방법은 COVID-19 코로나바이러스 변이주 감염 개체에서 아르기닌 대사에 관여하는 전사체 및 대사체의 변화를 확인함으로써, 효과적으로 COVID-19 코로나바이러스 변이주 감염을 진단할 수 있다.
BOPI
Electronic site
